Galectin-1-Specific Inhibitors as a New Class of Compounds To Treat HIV-1 Infection

Abstract excerpt

Despite significant improvements, antiretroviral therapies against HIV-1 are plagued by a high frequency of therapeutic failures that have been associated with acquisition of drug resistance. We recently reported that HIV-1 exploits a host glycan binding protein, galectin-1, to increase its attachment to host cells, thereby increasing its overall infectivity in susceptible cells. This finding suggests that host...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Galectins and Cancer Biology
• Share to Glycosylation and Glycoproteins Research
• Share to Peptidase Inhibition and Analysis